Revolution Medicines, Inc.

NASDAQ:RVMD

59.1 (USD) • At close November 7, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q4
Revenue 0000.74203.8247.01415.333.3569.1167.5789.461.1018.69810.1318.75112.66110.02511.54612.08812.50612.28113.16610.347
Cost of Revenue 012.775118.0212.8582.1451.7732.5332.59969.4552.3342.292.06246.47345.93640.85837.00634.87132.91827.45727.4922.96220.11721.18618.181
Gross Profit 0-12.775-118.021-2.116-2.1452.0514.48112.731-66.0996.7825.2887.398-45.372-37.238-30.727-28.255-22.21-22.893-15.911-15.402-10.456-7.836-8.02-7.834
Gross Profit Ratio 000-2.85200.5360.6390.83-19.6960.7440.6980.782-41.21-4.281-3.033-3.229-1.754-2.284-1.378-1.274-0.836-0.638-0.609-0.757
Reseach & Development Expenses 151.752134.932118.021146.867107.73597.98168.94766.12769.45561.00156.4953.68146.47345.93640.85837.00634.87132.91827.45727.4922.96220.11721.18618.181
General & Administrative Expenses 23.9621.71122.83832.24415.51314.6413.22410.9110.43410.2049.0378.6927.7917.2976.675.8255.3415.0915.1714.1623.1032.7252.4163.835
Selling & Marketing Expenses 000-1.24400000000000000000000
SG&A 23.9621.71122.8383115.51314.6413.22410.9110.43410.2049.0378.6927.7917.2976.675.8255.3415.0915.1714.1623.1032.7252.4163.835
Other Expenses 0-12.775-118.021000000000000000000000
Operating Expenses 175.712143.86822.838177.867123.248112.62182.17177.03779.88971.20565.52762.37354.26453.23347.52842.83140.21238.00932.62831.65226.06522.84223.60222.016
Operating Income -175.712-156.643-140.859-179.983-123.248-108.797-75.157-61.707-76.533-62.089-57.949-52.913-53.163-44.535-37.397-34.08-27.551-27.984-21.082-19.564-13.559-10.561-10.436-11.669
Operating Income Ratio 000-242.5650-28.451-10.715-4.025-22.805-6.811-7.647-5.593-48.286-5.12-3.691-3.894-2.176-2.791-1.826-1.618-1.084-0.86-0.793-1.128
Total Other Income Expenses Net 19.42423.4124.85618.78910.94710.4997.0595.0772.9070.8670.3020.2370.2230.2360.2210.2380.330.7110.8880.5950.7410.4420.3050.33
Income Before Tax -156.288-133.233-116.003-161.194-112.301-98.298-68.098-56.63-73.626-61.222-57.647-52.676-52.94-44.299-37.176-33.842-27.221-27.273-20.194-18.969-12.818-10.119-10.131-11.339
Income Before Tax Ratio 000-217.2430-25.706-9.709-3.694-21.939-6.716-7.607-5.568-48.084-5.093-3.67-3.867-2.15-2.72-1.749-1.569-1.025-0.824-0.769-1.096
Income Tax Expense -156.288000.3433.867-1.773-9.592-0.123-0.297-0.867-0.302-1.8250.2230.2360.2330.3620.347-0.058-0.675-4.3730.7660.470.3350.363
Net Income -156.288-133.233-116.003-161.537-108.434-98.298-58.506-56.507-73.329-60.355-57.345-52.676-52.94-44.299-37.176-34.204-27.221-27.215-19.519-14.596-12.818-10.119-10.131-11.339
Net Income Ratio 000-217.7050-25.706-8.341-3.686-21.85-6.621-7.567-5.568-48.084-5.093-3.67-3.909-2.15-2.715-1.691-1.207-1.025-0.824-0.769-1.096
EPS -0.94-0.81-0.7-1.14-0.99-0.92-0.62-0.63-0.87-0.81-0.77-0.71-0.72-0.6-0.53-0.52-0.42-0.46-0.67-0.4-0.35-0.28-0.28-0.31
EPS Diluted -0.94-0.81-0.7-1.14-0.99-0.92-0.62-0.63-0.87-0.81-0.77-0.71-0.72-0.6-0.53-0.52-0.42-0.46-0.67-0.4-0.35-0.28-0.28-0.31
EBITDA -175.712-154.934-139.352-177.125-123.248-108.797-75.157-56.63-71.193-58.888-55.357-52.676-51.189-42.458-35.486-33.828-25.574-25.583-18.629-18.081-11.92-9.28-9.308-10.615
EBITDA Ratio 000-238.7130-28.451-10.715-3.694-21.214-6.46-7.305-5.568-46.493-4.881-3.503-3.866-2.02-2.552-1.613-1.496-0.953-0.756-0.707-1.026